PERCEPTIVE ADVISORS LLC
CIK 1224962 · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.17B
Companies
29
Total Filings
76
Lifetime Open-Market Net
$647.93M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMTX | Director | — | $8.73 | — | $0 | 1 | 2026-06-18 |
| MGTX | Director | 11,281,103 | $11.82 | $133.34M | $178.27M | 9 | 2026-06-15 |
| SLDB | Director | 73,107 | $7.97 | $582.7K | $80.60M | 7 | 2026-06-11 |
| ADGM | Director | 9,876,586 | $0.45 | $4.42M | $0 | 1 | 2025-02-14 |
| NAUT | Director | — | $1.20 | — | $0 | 3 | 2024-06-17 |
| VRCA | 10%+ Owner | 672,291 | $5.40 | $3.63M | $54.77M | 2 | 2023-12-26 |
| SOLENO THERAPEUTICS INC (SLNO) Delisted | 10%+ Owner | 2,270,473 | $53.01 | $120.36M | $45.34M | 1 | 2023-09-28 |
| LianBio (LIAN) Delisted | Director | — | $0.32 | — | $0 | 2 | 2023-06-23 |
| Lyra Therapeutics, Inc. (LYRA) Delisted | Director | 25,769 | $0.70 | $18.0K | $36.00M | 2 | 2023-06-02 |
| CHEMBIO DIAGNOSTICS, INC. (CEMI) Delisted | 10%+ Owner | 4,863,334 | $0.46 | $2.21M | $451.2K | 2 | 2023-04-20 |
| ALDX | 10%+ Owner | 10,801,985 | $1.58 | $17.07M | $11.27M | 2 | 2022-08-04 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 4,843,095 | $18.07 | $87.51M | $15.00M | 1 | 2021-07-09 |
| VBI Vaccines Inc/BC (VBIV) Delisted | 10%+ Owner | 0 | $0.07 | $0 | $35.56M | 3 | 2021-06-30 |
| Landos Biopharma, Inc. (LABP) Delisted | Director | 294,177 | $22.93 | $6.75M | $100.00M | 1 | 2021-02-08 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 1 | 2021-02-03 |
| Motus GI Holdings, Inc. (MOTS) Delisted | 10%+ Owner | 10,702 | $0.00 | $1 | $10.79M | 3 | 2021-01-22 |
| CRNX | 10%+ Owner | 3,659,381 | $83.86 | $306.88M | $45.00M | 1 | 2020-04-20 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | 10%+ Owner | 1,960,139 | $44.15 | $86.54M | $16.12M | 1 | 2020-02-04 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 20,724,424 | $14.49 | $300.30M | $0 | 1 | 2019-02-19 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | 10%+ Owner | 4,313,611 | $6.22 | $26.83M | $79.13M | 2 | 2018-03-26 |
| Corium International, Inc. (CORI) Delisted | 10%+ Owner | 5,847,133 | — | — | $6.96M | 1 | 2017-07-05 |
| TALPHERA, INC. (ACRX) Delisted | 10%+ Owner | 323,378 | $0.86 | $278.1K | $11.38M | 2 | 2013-11-12 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 2,823,426 | — | — | -$153.82M | 4 | 2013-09-09 |
| REPROS THERAPEUTICS INC. (RPRX.Z) Delisted | 10%+ Owner | — | — | — | $0 | 4 | 2013-02-13 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2011-11-09 |
| REPROS THERAPEUTICS INC. (RPRXZ) Delisted | 10%+ Owner | 1,982,460 | — | — | $12.38M | 3 | 2011-08-24 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | 10%+ Owner | 6,476,446 | — | — | $279.5K | 7 | 2009-03-31 |
| IDEV | 10%+ Owner | 7,891,067 | $89.42 | $705.62M | $5.16M | 2 | 2009-03-09 |
| XTLB | 10%+ Owner | 153,459 | $2.96 | $454.2K | $57.30M | 5 | 2008-06-11 |
Recent Filings · Page 4 of 8
76 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-24 | MGTX | Buy (P) | +1,500,000 | $19.27M | EDGAR |
| 2020-06-18 | SLDB | Grant (A) | — | $0 | EDGAR |
| 2020-05-01 | Lyra Therapeutics, Inc. (LYRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-20 | CRNX | Buy (P) | +3,214,284 | $45.00M | EDGAR |
| 2020-02-04 | ALBIREO PHARMA, INC. (ALBO) Delisted | Buy (P) | +767,427 | $16.12M | EDGAR |
| 2019-08-20 | MGTX | Buy (P) | +1,276,593 | $30.00M | EDGAR |
| 2019-03-05 | MGTX | Buy (P) | +3,913,044 | $54.00M | EDGAR |
| 2019-02-19 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | — | — | $0 | EDGAR |
| 2019-01-17 | Motus GI Holdings, Inc. (MOTS) Delisted | Buy (P) | +1,230,000 | $3.39M | EDGAR |
| 2018-12-17 | VBI Vaccines Inc/BC (VBIV) Delisted | Buy (P) | +42,857,142 | $60.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.